PATENT COOPERATION TREAT

PCT

REC'D	23	MAR	2005	

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

			- N - 61 6						
Applicant's or agent's file reference 100884-1 WO		FOR FURTHER A	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)			ational PCT/IPEA/416)			
International application No. International filing data PCT/SE 03/01706 05.11.2003			(day/month	lyear)	Priority date (day/moni	th/year)			
	International Patent Classification (IPC) or both national classification and IPC C07 D295/155								
	Applicant ASTRAZENECA AB et al.								
1.	 This International preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 								
2.	This	REP	ORT consists of a total	of 6 sheets, including t	nis cover s	sheet.			
	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).								
	These annexes consist of a total of sheets.								
3.	3. This report contains indications relating to the following items:								
	I ⊠ Basis of the opinion								
	II		Priority						
İ	III	\boxtimes	•	opinion with regard to n	oveity in	ventive sten a	nd industrial applicabl	lite	
	IV		Lack of unity of invent		applicability				
	٧	×	Reasoned statement	under Rule 66.2(a)(ii) w lons supporting such st	ith regard atement	to novelty, in	ventive step or industr	ial applicability;	
	VI	\boxtimes	Certain documents cit	ed					
	VII		Certain defects in the	international applicatior	1				
	VIII		Certain observations of	on the international app	lication				
Date of submission of the demand			Date of completion of this report						
14.05.2004			22.03.2005			•			
Name and mailing address of the international preliminary examining authority:			Authorized Officer						
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465				Cortés,	J e No. +49 89 2	399-8206			

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE 03/01706

l.	Basis	of	the	re	port
----	--------------	----	-----	----	------

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Description, Pages						
	1-108		as originally filed				
	.						
	Clai	ms, Numbers					
	1-21		as originally filed				
2.	With lang	n regard to the langu a juage in which the inte	age, all the elements marked above were available or furnished to this Authority in the ernational application was filed, unless otherwise indicated under this item.				
	The	se elements were ava	ailable or furnished to this Authority in the following language: , which is:				
		the language of a tra	nslation furnished for the purposes of the international search (under Rule 23.1(b)).				
		the language of publi	cation of the international application (under Rule 48.3(b)).				
		the language of a tra Rule 55.2 and/or 55.3	nslation furnished for the purposes of international preliminary examination (under 3).				
3.	With inte	n regard to any nucle rnational preliminary e	otide and/or amino acid sequence disclosed in the international application, the examination was carried out on the basis of the sequence listing:				
		contained in the inter	mational application in written form.				
		filed together with the	e international application in computer readable form.				
		furnished subsequer	ntly to this Authority in written form.				
☐ furnished subsequently to this Authority in computer readable form.							
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.						
		The statement that the listing has been furnitude.	he information recorded in computer readable form is identical to the written sequence ished.				
4.	The	amendments have re	esulted in the cancellation of:				
		the description,	pages:				
		the claims,	Nos.:				
		the drawings,	sheets:				
5.		This report has been been considered to	n established as if (some of) the amendments had not been made, since they have go beyond the disclosure as filed (Rule 70.2(c)).				
		(Any replacement sl report.)	heet containing such amendments must be referred to under item 1 and annexed to this				
6.	Add	ditional observations,	if necessary:				

INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

International application No. PCT/SE 03/01706

ił.	NOT	n-establishment of opinion with	ın rega	ara to novell	ty, inventive step	and industrial applicability		
۱.	The obv	ne questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- ovious), or to be industrially applicable have not been examined in respect of:						
	\square the entire international application,							
⊠ claims Nos. 14-16								
		because:						
the said international application, or the said claims Nos. 14-16 relate to the following subject mate does not require an international preliminary examination (specify):								
		see separate sheet						
the description, claims or drawings (indicate particular elements below) or said claims Nos. are so un that no meaningful opinion could be formed (specify):								
		the claims, or said claims Nos. could be formed.	are so	o inadequatel	ly supported by the	description that no meaningful opinion		
		no international search report l	has be	en establishe	ed for the said clair	ns Nos.		
2.	or a	A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:						
		the written form has not been	furnish	ed or does n	ot comply with the	Standard.		
		the computer readable form ha	as not	been furnish	ed or does not com	ply with the Standard.		
V.		Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability citations and explanations supporting such statement						
1. Statement			• •					
	No	velty (N)	Yes: No:	Claims Claims	1-21			
	Inv	rentive step (IS)	Yes: No:	Claims Claims	1-21			
	Inc	dustrial applicability (IA)	Yes: No:	Claims Claims	1-13, 17-21			
2	. Cit	ations and explanations				· .,		

see separate sheet

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE 03/01706

VI. Certain documents cited

 Certain published documents (Rule 70.10) and / or

Non-written disclosures (Rule 70.9)see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 14-16 relate to subject matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject matter of these claims (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The following documents have been cited in the International Search Report:

D1: WO 93 15062 A1

D2: PLOBECK NIKLAS ET AL.: 'New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased in vitro metabolic stability', J. MED. CHEM., vol. 43, 2000, pages 3878 - 3894, XP002973657

Novelty (Article 33(2) PCT)

The present compounds are a new selection of the compounds in D1. They differ from the structurally closest related examples 32 and 33 in that the piperazine is unsubstituted in positions 2,3,5 and 6.

The process of claim 18 differs from the process in D2 (scheme 9) in the nitro substituent of the final product.

The present claim set is therefore novel.

Inventive Step (Article 33(3) PCT)

D1 generically discloses the present compounds as well as their medical use. D1 can be regarded as the closest prior art.

The problem of the invention was the provision of new compounds for the treatment of

pain or gastrointestinal disorders.

Since the present compounds as well as their medical use have been generically disclosed in D1 the present application lacks an inventive step.

Re Item VI Certain documents cited

Reference is made to the following P-documents:

D3: WO 02 094794 A1

The priority documents pertaining to the present application were not available at the time of establishing this report. Hence, it is based on the assumption that all claims enjoy priority rights from the filing date of the priority document. If it later turns out that this is not correct, the P-document cited in the international search report could become relevant to asses whether the present claims satisfy the criteria set forth in Article 33(1) PCT.